65 results on '"Dalton, William S."'
Search Results
2. Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance
3. Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker
4. Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas
5. Systems Biology Analysis Identifies Targetable Vulnerability Networks to Proteasome Inhibitors in Multiple Myeloma
6. A Systems Biology Approach to Identify Mechanisms of Therapy Resistance in Multiple Myeloma
7. The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma
8. Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma
9. B Cell Receptor (BCR) Signal Pathways Confer Microenvironment-Mediated Drug Resistance and Are Promising Therapeutic Targets for B Cell Lymphomas
10. Silencing c-Myc Using Myc Inhibitor JQ1 and EZH2 Inhibitor DZNep Blocks Converging Survival Signals in Aggressive B-Cell Lymphomas
11. Targeting Mir-548m-HDAC6 Axis Circumvents Stroma- Mediated Drug Resistance (CAM-DR) and Clonogenicity in Non-Hodgkin B-Cell Lymphomas
12. Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis
13. Pyk2 Mediates Enhanced STAT3 Phosphorylation Following Collaborative Signaling Between gp130 and beta1 Integrins in Adhered Myeloma and B Cells
14. Follicular dendritic cell–dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion–mediated Bim down-regulation through induction of microRNA-181a
15. Myc Represses miR15a/Mir-16-1 Expression through Recruitment of HDAC3 In Mantle Cell Lymphoma
16. Microenvironment-Mediated Regulation of Micrornas In B-Lymphocytes as a Novel Mechanism for Terminal B-Cell Differentiation and Lymphomagenesis.
17. Selected Resistance to Topoisomerase II Inhibitors Correlates with the Over Expression of FANCF In a Fanconi Anemia/BRCA DNA Repair Pathway Independent Manner.
18. Characterization of Clonal Pre-B Cell Progenitors of Plasma Cells In Multiple Myeloma
19. Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)
20. Treatments and Outcomes of Patients with Multiple Myeloma (MM) Older Than 75 Years of Age: A Single Institution Experience
21. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma
22. Follicular Dendritic Cell (FDC)-Induced Microrna-Mediated up-Regulation of PRDM1 and Down-Regulation of BCL6 in Germinal Center B Lymphocytes: A Potential Mechanism for B-Cell Differentiation.
23. A Novel Upregulation of Fanconi Anemia/BRCA DNA Repair Pathway Is Observed Upon Co-Culture of Bone Marrow Stroma with Multiple Myeloma Cell Lines: A Potential New Participant(s) in Environment Mediated Drug Resistance.
24. Bortezomib Reverts Stroma-Mediated Resistant to APO2L/TRAIL in Multiple Myeloma.
25. MiR-29 MicroRNAs Regulate IGF-1R Expression and Contribute Mantle Cell Lymphoma Growth and Survival.
26. Phase I Study of Bortezomib(Bz), Pegylated Doxorubicin(DOX) and Dexamethasone(dex); ( VDD) with Escalating Doses of Cyclophosphamide(Cy) in Patients with Newly Diagnosed Myeloma.
27. Influence of Targeted Therapy in Redefining High-Risk Myeloma.
28. Use of MicroRNA Expression Profiling to Identify Prognostic Subclasses in Mantle Cell Lymphoma: Mir-29 Family as New Prognostic Markers
29. Age Is the Strongest Independent Prognostic Factor in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: Moffitt Cancer Center Experience
30. β1 Integrin Adhesion Enhances IL-6 Mediated STAT3 Signaling in Multiple Myeloma Cells: Implications for Microenvironment Influence on Tumor Cell Survival and Proliferation.
31. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy
32. NF-kB as a Regulator of FA/BRCA Gene Expression in Multiple Myeloma.
33. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas
34. ABCG2 expression, function, and promoter methylation in human multiple myeloma
35. Bortezomib Enhances Melphalan Response by Altering Fanconi Anemia (FA)/BRCA Pathway Expression and Function.
36. Hematopoietic Stroma Confers Resistance to Immune Control by TRAIL in Multiple Myeloma through Induction of FLIP.
37. A New Target in Multiple Myeloma: Inhibition of Notch Pathway Induces Apoptosis and Enhances Drug Sensitivity of Myeloma Cells In Vitro and In Vivo.
38. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
39. Bone Marrow Stroma (BMS) Prevents Apoptosis of Lymphoma Cells by Upregulation of BMS-Derived B-Cell Activating Factor (BAFF) and Activation of NF-kB.
40. Cell Adhesion Induces p27Kip1-Associated Cell-Cycle Arrest through Down-Regulating SCFSkp2 Ubiquitin Ligase Pathway in Mantle Cell and Other Non-Hodgkin’s B-Cell Lymphomas.
41. The Proteasome Inhibitor PR-171 Inhibits Cell Growth, Induces Apoptosis, and Overcomes De Novo and Acquired Drug Resistance in Human Multiple Myeloma Cells.
42. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells
43. Characterization of a R115777 Resistant Human Multiple Myeloma Cell Line with Cross-Resistance to PS-341.
44. HSP70 Induces IL-6 in Stromal Cells and Stat-3 Activation in Myeloma Cells.
45. Adhesion of 8226 Myeloma Cell Lines Induces over Expression of HSP70 and its Inhibition Reverses CAM-DR and Acquired Drug Resistance in Multiple Myeloma.
46. β1 Integrin Activation Via FN Adhesion Enhances IL-6 Response in Myeloma Cells.
47. Enhanced DNA Repair Via Fanconi Anemia/BRCA Pathway Is Involved in Melphalan-Resistant Myeloma Cells.
48. Influence of Fibronectin,(FN), Adhesion on Gene Expression Profiles, (GEP), of Isolated Patient Myeloma Cells.
49. Bortezomib-Induced Reversal of CAM-DR Phenotype in Myeloma Is Associated with AKT and ERK1/2 Signaling.
50. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.